Enrichment of ALDH+ cells after treatment
| . | Granta 519 . | Jeko-1 . | Rec-1 . |
|---|---|---|---|
| Dexamethasone | 2.09 ± 0.79 | 3.18 ± 0.09* | 4.01 ± 1.37 |
| Etoposide | 1.32 ± 0.22 | 1.49 ± 0.35 | 2.29 ± 1.12 |
| Bortezomib | 1.20 ± 0.13 | 2.14 ± 0.60 | 1.98 ± 0.55 |
| . | Granta 519 . | Jeko-1 . | Rec-1 . |
|---|---|---|---|
| Dexamethasone | 2.09 ± 0.79 | 3.18 ± 0.09* | 4.01 ± 1.37 |
| Etoposide | 1.32 ± 0.22 | 1.49 ± 0.35 | 2.29 ± 1.12 |
| Bortezomib | 1.20 ± 0.13 | 2.14 ± 0.60 | 1.98 ± 0.55 |
Fold change in the proportion of ALDH+ cells after 48 hours of treatment with dexamethasone (1nM), etoposide (0.1nM), or bortezomib (10nM) relative to vehicle-treated cells. Values represent the mean ± SEM from 4 independent experiments in each cell line. Aldefluor+ populations were defined by diethylaminobenzaldehyde control–treated cells for all samples.
P < .01.